In 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing. TAG conducted this second survey in the fall of 2019 to track any changes over time and provide updated information on status of the field.
Treatment Action Group (TAG) is profoundly saddened by the news that Timothy Ray Brown—the first person in the world considered cured of HIV infection—died yesterday from a recurrence of cancer.
This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.
Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”
Treatment Action Group (TAG) strongly condemns alleged bullying, harassment, and racism directed toward staff and contractors of the Stop TB Partnership, as reported by The New York Times. As a long-term and current grantee of the Stop TB Partnership, we stand in solidarity with current and former staff and contractors whom this harassment and racism has affected.
In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.
Our publication, An Activist’s Guide to Tuberculosis Diagnostic Tools, details the latest WHO recommendations, the array of available TB diagnostic tools, and how these tools should be optimally used in country programs, including to support TB screening and diagnosis among special populations such as children, people with extrapulmonary TB, and people living with HIV/AIDS (PLWHA).
TAG and the Center for Economic and Social Rights produced this joint publication, as part of CESR’s COVID-19 “Recovering Rights” series of briefs.
Two recent developments have brought renewed publicity to proposals to conduct human challenge studies to test COVID-19 vaccine candidates: an open letter from the organization 1DaySooner and media reports that Adrian Hill’s Oxford University research group is planning a challenge study, taking advantage of the lack of regulatory oversight of human challenge experiments in the United Kingdom.
Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).